Early-Onset Cancers: Investigating Etiology, Mechanisms, and Early Detection Strategies (RP1 Clinical Trials Optional)
- Response deadline
- Oct 11, 2029 Due in 1092 days
- Date posted
- Oct 14, 2026
- Source
- Open notice
Description
This Notice of Funding Opportunity (NOFO) invites applications that investigate the etiology of sporadic non-hereditary early-onset cancers (EOCs: ages 18 to 49 years) and the underlying biological mechanisms that play a role in these cancers to inform prevention and control strategies. The proposed research is expected to advance the understanding of the unexplained rise of cancers in young adults. More specifically, studies should focus on one or more of the following: i) identifying what environmental or lifestyle exposures are driving the increase in the incidence of non-hereditary EOCs, and how these factors vary by patient demographics; ii) examining the biological mechanisms and host responses that underlie the increase in EOCs; and iii) identifying how those at increased risk of developing EOCs can be identified more effectively. In an effort to streamline the application process and sustain momentum in this critical research area, this NOFO supports both exploratory/developmental and standard research projects through a grant award instrument.
Classifications
- NAICS93.113
Documents (1)
- PAR-28-014-Full-Announcement.htmltext/html;charset=UTF-8128 KBNot yet available
Contacts
Similar contracts
- NIH Research Program Projects (Parent P01 Clinical Trial Optional)Due May 25, 2029
- Environmental Health Sciences Core Centers Program (P30 Clinical Trials Optional)Due Apr 20, 2027
- NIH Research Software Engineer (RSE) Award (R50 Clinical Trials Not Allowed)Due Dec 4, 2026
- Advancing Bioinformatics, Translational Bioinformatics and Computational Biology Research (R01 Clinical Trial Optional)Due Mar 5, 2029
- NIA Expanding Research in AD/ADRD (ERA) Summer Research Education Program (R25 Independent Clinical Trial Not Allowed)Due May 26, 2027
- Stimulating Access to Research in Residency (StARR) (R38 Independent Clinical Trial Not Allowed)Due Jan 10, 2028